Global warming has brought a drastic change in the climatic conditions all over the world. Due to this, there has been noticed, an increase in the mosquitoes-borne diseases that has badly affected the health of larger human populations. This incidence is known as one of the major health concerns worldwide.

In lieu of this, the Australian infectious disease therapy and vaccine development company BioDiem Ltd has signed an exclusive licensing agreement with Australian National University (ANU). It allows the former company to commercialize a novel vaccine technology from the John Curtin School of Medical Research at ANU.

Though this vaccination is purposely designed to fight against Dengue Fever, there are chances that the technology behind it may also allow it to treat various other infectious diseases like Murray River encephalitis and Japanese encephalitis. By accepting the agreement, BioDiem gets the provision to sublicense the technology.

Around 50 to 100 million people become the victim of Dengue Fever every year. Though only a few of them are considered to be fatal, the non-fatal cases can also prove to be extremely devastating sometimes.

Till now, no such vaccination has been designed for Dengue Fever but there are certain techniques following which mosquito populations can be controlled.